Pulse Biosciences Reports Strong Long-Term Clinical Data for Thyroid Nodule Ablation System

summarizeSummary

Pulse Biosciences reported positive long-term clinical data for its nPulse Vybrance system in treating benign thyroid nodules, showing durable volume reduction and high patient satisfaction.

check_boxKey Events

• Durable Clinical Efficacy

  The nPulse Vybrance system achieved an average 74% volume reduction of treated benign thyroid nodules, sustained over 15-22 months, with no regrowth.

• High Patient Satisfaction & Safety

  Patients reported 100% cosmetic satisfaction and 95% overall satisfaction, with no serious adverse events or intranodular fibrosis detected.

• Expanded Market Potential

  These positive long-term results for benign thyroid nodules demonstrate the potential for the company's nsPFA technology beyond its cardiac applications.

auto_awesomeAnalysis

Pulse Biosciences announced highly positive long-term follow-up data from its nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules. The study demonstrated durable 74% volume reduction, no regrowth, and high patient satisfaction (100% cosmetic, 95% overall) over 15-22 months, with no serious adverse events. This strong clinical evidence for a non-cardiac application of their nsPFA technology could significantly expand the company's market opportunities and provides a foundation for future development and commercialization efforts.